Low YKL-40 in chronic heart failure may predict beneficial effects of statins: analysis from the controlled rosuvastatin multinational trial in heart failure (CORONA)

Biomarkers

Volumn 22, Issue 3-4, 2017, Pages 261-267

  Arain, Fizza ^a,b   Gullestad, Lars ^a,b,c   Nymo, Ståle ^a   Kjekshus, John ^a,b,c   Cleland, John G ^d   Michelsen, Annika ^a   McMurray, John J ^e   Wikstrand, John ^f   Aukrust, Pål ^a,b,c,f   Ueland, Thor ^a,b,c,g  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

^d UNIVERSITY OF HULL   (United Kingdom)

^e UNIVERSITY OF GLASGOW   (United Kingdom)

^f SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^g UNIVERSITY OF TROMSØ   (Norway)

Author keywords

Heart failure; mortality; risk prediction; YKL 40

Indexed keywords

CHITINASE 3 LIKE PROTEIN 1; PLACEBO; ROSUVASTATIN; CHI3L1 PROTEIN, HUMAN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

AGED; ARTICLE; CARDIAC PATIENT; CARDIOVASCULAR MORTALITY; CONTROLLED STUDY; DRUG RESPONSE; ENZYME IMMUNOASSAY; FEMALE; HEART FAILURE; HUMAN; IMMUNOASSAY ANALYZER; ISCHEMIC HEART DISEASE; ISCHEMIC HEART FAILURE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PROGNOSIS; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; BLOOD; CHRONIC DISEASE; CLINICAL TRIAL; MULTICENTER STUDY; PREDICTIVE VALUE; TREATMENT OUTCOME;

AGED; CHITINASE-3-LIKE PROTEIN 1; CHRONIC DISEASE; FEMALE; HEART FAILURE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; ROSUVASTATIN CALCIUM; TREATMENT OUTCOME;

EID: 84978152295     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.1080/1354750X.2016.1204003     Document Type: Article

References (31)

1. Askevold ET, Gullestad L, Nymo S, et al. (2015). Secreted frizzled related protein 3 in chronic heart failure:analysis from the controlled Rosuvastatin multinational trial in heart failure (CORONA). PLoS One 10:e0133970.
2. Bartunek J., (2009). Biomarkers:old-new, cardiac-noncardiac, all paving the way for better stratification in heart failure. Foreword. Biomark. Med 3:435–7.
3. Bilim O, Takeishi Y, Kitahara T, et al. (2010). Serum YKL-40 predicts adverse clinical outcomes in patients with chronic heart failure. J Card Fail 16:873–9.
4. Braunwald E., (2013). Heart failure. JACC Heart Fail 1:1–20.
5. Cleland JG, McMurray JJ, Kjekshus J, et al. (2009). Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure:prediction of cardiovascular events and interaction with the effects of rosuvastatin:a report from CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure). J Am Coll Cardiol 54:1850–9.
6. Dalzell JR, Cannon JA, Jackson CE, et al. (2014). Emerging biomarkers for heart failure:an update. Biomark Med 8:833–40.
7. Deardorff R, Spinale FG., (2009). Cytokines and matrix metalloproteinases as potential biomarkers in chronic heart failure. Biomark Med 3:513–23.
8. Gastelurrutia P, Lupon J, Bayes-Genis A., (2013). Statins in heart failure:not yet the end of the story? Eur J Heart Fail 15:708–9.
9. Gullestad L, Ueland T, Kjekshus J, et al. (2012). Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Eur Heart J 33:2290–6.
10. Harutyunyan M, Christiansen M, Johansen JS, et al. (2012). The inflammatory biomarker YKL-40 as a new prognostic marker for all-cause mortality in patients with heart failure. Immunobiology 217:652–6.
11. Harutyunyan M, Gotze JP, Winkel P, et al. (2013). Serum YKL-40 predicts long-term mortality in patients with stable coronary disease:a prognostic study within the CLARICOR trial. Immunobiology 218:945–51.
12. Hedegaard A, Ripa RS, Johansen JS, et al. (2010). Plasma YKL-40 and recovery of left ventricular function after acute myocardial infarction. Scand J Clin Lab Invest 70:80–6.
13. Johansen JS., (2006). Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer. Dan Med Bull 53:172–209.
14. Johansen JS, Bojesen SE, Tybjaerg-Hansen A, et al. (2010). Plasma YKL-40 and total and disease-specific mortality in the general population. Clin Chem 56:1580–91.
15. Kastrup J., (2012). Can YKL-40 be a new inflammatory biomarker in cardiovascular disease? Immunobiology 217:483–91.
16. Kastrup J, Johansen JS, Winkel P, et al. (2009). High serum YKL-40 concentration is associated with cardiovascular and all-cause mortality in patients with stable coronary artery disease. Eur Heart J 30:1066–72.
17. Kjekshus J, Apetrei E, Barrios V, et al. (2007). Rosuvastatin in older patients with systolic heart failure. N Engl J Med 357:2248–61.
18. Kucur M, Isman FK, Karadag B, et al. (2007). Serum YKL-40 levels in patients with coronary artery disease. Coron Artery Dis 18:391–6.
19. McMurray JJ, Kjekshus J, Gullestad L, et al. (2009). Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA):a retrospective analysis. Circulation 120:2188–96.
20. Michelsen AE, Rathcke CN, Skjelland M, et al. (2010). Increased YKL-40 expression in patients with carotid atherosclerosis. Atherosclerosis 211:589–95.
21. Mosterd A, Hoes AW., (2007). Clinical epidemiology of heart failure. Heart 93:1137–46.
22. Mygind ND, Harutyunyan MJ, Mathiasen AB, et al. (2011). The influence of statin treatment on the inflammatory biomarkers YKL-40 and HsCRP in patients with stable coronary artery disease. Inflamm Res 60:281–7.
23. Pencina MJ, D'agostino RB, Sr., Steyerberg EW., (2011). Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 30:11–21.
24. Pencina MJ, D'agostino RB, Vasan RS., (2010). Statistical methods for assessment of added usefulness of new biomarkers. Clin Chem Lab Med 48:1703–11.
25. Rathcke CN, Kistorp C, Raymond I, et al. (2010). Plasma YKL-40 levels are elevated in patients with chronic heart failure. Scand Cardiovasc J 44:92–9.
26. Ueland T, Aukrust P, Nymo SH, et al. (2015). Novel extracellular matrix biomarkers as predictors of adverse outcome in chronic heart failure:association between biglycan and response to statin therapy in the CORONA trial. J Card Fail 21:153–9.
27. Volck B, Price PA, Johansen JS, et al. (1998). YKL-40, a mammalian member of the chitinase family, is a matrix protein of specific granules in human neutrophils. Proc Assoc Am Physicians 110:351–60.
28. von HS., (2009). Statins for heart failure:still caught in no man’s land? Clin Sci (Lond) 116:37–9.
29. Wang Y, Ripa RS, Johansen JS, et al. (2008). YKL-40 a new biomarker in patients with acute coronary syndrome or stable coronary artery disease. Scand Cardiovasc J 42:295–302.
30. Wedel H, McMurray JJ, Lindberg M, et al. (2009). Predictors of fatal and non-fatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA):incremental value of apolipoprotein A-1, high-sensitivity C-reactive peptide and N-terminal pro B-type natriuretic peptide. Eur J Heart Fail 11:281–91.
31. Zelen M., (1971). The analysis of several 2x2 contingency tables. Biometrika 58:129–37.